Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
110Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $572.98M | $-61.42M | $-2.04 |
| 2024 | $575.92M | $-128.17M | $-4.19 |
| 2023 | $550.21M | $-28.20M | $-0.93 |
| 2022 | $430.53M | $7.98M | $0.46 |
| 2021 | $388.51M | $20.62M | $0.70 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-0.21 per share
Typical surprise -16.9% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.39 vs $-0.33miss
- Fri, May 8$-0.58 vs $-0.64beat
- Fri, Mar 13$-0.61 vs $-0.46miss
- Mon, Nov 10$-0.35 vs $-0.28miss
- Thu, Aug 7$-0.40 vs $-0.37miss
- Mon, May 12$-0.67 vs $-0.56miss
Estimates and results for CNTY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CNTYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Positive
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming
View source ↗